Results 191 to 200 of about 83,454 (234)

Targeted delivery of antisense oligonucleotides in cancer

Journal of Controlled Release, 2001
Formulations of antisense oligonucleotides (asODNs) against c-myb or c-myc protooncogenes have been prepared by a new technique that sequesters cationic lipid in the interior of a lipid particle. This technique results in high loading efficiency for the asODNs, small particle size and good stability.
F, Pastorino, D, Stuart, M, Ponzoni, T M, Allen   +3 more
openaire   +2 more sources

Antisense Technology: Selection and Delivery of Optimally Acting Antisense Oligonucleotides

Journal of Drug Targeting, 1998
AbstractAntisense technology has increasingly become a reality. It's objective is simple: to inhibit gene expression in a highly sequence-specific and selective manner. The technology has come to encompass three distinct strategies: antigene and antisense oligonucleotides (ODNs) and ribozymes.
openaire   +2 more sources

Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides

Pharmaceutical Research, 1999
This review critically examines current understanding of the kinetics and biodistribution of antisense oligonucleotides, both at the cellular level and at the level of the intact organism. The pharmacodynamic relationships between biodistribution and the ultimate biological effects of antisense agents are considered.
R L, Juliano, S, Alahari, H, Yoo, R, Kole, M, Cho   +4 more
openaire   +2 more sources

Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides

Journal of Medicinal Chemistry, 2020
Despite recent advances, targeted delivery of therapeutic oligonucleotide to extra-hepatic tissues continues to be a challenging endeavor and efficient ligand-receptor systems need to be identified. To determine the feasibility of using neurotensin to improve the productive uptake of antisense oligonucleotides (ASO), we synthesized neurotensin-ASO ...
Mehran Nikan, Michael Tanowitz, Chrissa A. Dwyer, Michaela Jackson, Hans J. Gaus, Eric E. Swayze, Frank Rigo, Punit P. Seth, Thazha P. Prakash   +8 more
openaire   +2 more sources

Oral delivery of siRNA and antisense oligonucleotides

Journal of Drug Targeting, 2009
Inhibition of gene expression with antisense oligonucleotides or RNA interference (RNAi) mediated gene silencing by small interfering RNA (siRNA) has tremendous potential to silence the expression of disease-causing genes in the clinic. A major hurdle to their widespread clinical use is the safe and efficient delivery to target cells in vivo.
openaire   +2 more sources

PAMAM Dendrimers as Delivery Agents for Antisense Oligonucleotides

Pharmaceutical Research, 1999
To investigate the potential use of PAMAM dendrimers for the delivery of antisense oligonucleotides into cells under conditions that mimic the in vivo environment.We used HeLa cells stably transfected with plasmid pLuc/705 which has a luciferase gene interrupted by a human beta-globin intron mutated at nucleotide 705, thus causing incorrect splicing ...
H, Yoo, P, Sazani, R L, Juliano
openaire   +2 more sources

Delivery of Antisense Oligonucleotides to the Vascular Wall

2003
Antisense oligonucleotides are short segments of synthetic DNA designed to contain sequences of bases complementary to the DNA or RNA of a particular target gene of interest. By binding to the target, the antisense oligonucleotides can prevent translation of the gene into protein via different mechanisms including destruction of the AS-ODN-nucleic acid
Holt, Cathy M, Gunn, Julian, Lambert, Darren, Cumberland, David C, Crossman, David C   +4 more
openaire   +3 more sources

The cellular delivery of antisense oligonucleotides and ribozymes

Drug Discovery Today, 2001
The design and development of antisense oligonucleotides and ribozymes for the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. Improvements in oligonucleotide chemistry have led to the synthesis of nucleic acids that are relatively stable in the biological milieu.
M D., Hughes, M, Hussain, Q, Nawaz, P, Sayyed, S, Akhtar   +4 more
openaire   +2 more sources

Intracellular Delivery Strategies for Antisense Phosphorodiamidate Morpholino Oligomers

Antisense and Nucleic Acid Drug Development, 2000
Antisense oligonucleotides inhibit gene expression by interfering with transcription, translation, or splicing. They show great potential as gene-specific, nontoxic therapy for a wide variety of diseases. They are also powerful tools to study gene function as well as for validation of therapeutic targets.
C, Ghosh, P L, Iversen
openaire   +2 more sources

Nanoparticulate systems for the delivery of antisense oligonucleotides

Advanced Drug Delivery Reviews, 2001
Antisense oligonucleotides are molecules that are able to inhibit gene expression being therefore potentially active for the treatment of viral infections or cancer. However, because of their poor stability in biological medium and their weak intracellular penetration, colloidal drugs carriers such as nanoparticles were developed for the delivery of ...
G, Lambert, E, Fattal, P, Couvreur
openaire   +2 more sources